| Yu-Hua Chou |
------>authors3_c= ------>paper_class1=2 ------>Impact_Factor=None ------>paper_class3=0 ------>paper_class2=0 ------>vol=ISNCC ------>confirm_bywho=clin ------>insert_bywho=chou ------>Jurnal_Rank=None ------>authors4_c= ------>comm_author= ------>patent_EDate=None ------>authors5_c= ------>publish_day=17 ------>paper_class2Letter=None ------>page2= ------>medlineContent= ------>unit=H0100 ------>insert_date=20081124 ------>iam=1 ------>update_date=None ------>author=??? ------>change_event=4 ------>ISSN= ------>authors_c=??? ------>score=-1000 ------>journal_name=The International Society of Nurses in Cancer Care (ISNCC) “Creating Partnerships, Championing Progress and Celebrating Practice”, in Singapore ------>paper_name=Concerns & Needs for Family Caregivers of Patient With Gynecological cancer–A Qualitative Approach ------>confirm_date=20090928 ------>tch_id=089111 ------>pmid=19921283 ------>page1=121 ------>fullAbstract=INTRODUCTION: Anaemia during chemotherapy is often left untreated. Erythropoiesis-stimulating agents are frequently used to treat overt anaemia. Their prophylactic use, however, remains controversial and raises concerns about cost-effectiveness. Therefore, we assessed the efficacy of a dose-reduction schedule in anaemia prophylaxis. MATERIALS AND METHODS: The study included patients with untreated solid tumours about to receive platinum-based chemotherapy and had haemoglobin (Hb) levels >/=11 g/dL. Epoetin-alpha was administered at a dose level of 3 x 10,000 U weekly as soon as Hb descended to < 13 g/dL. Dose reductions to 3 x 4,000 U and 3 x 2,000 U weekly were planned in 4-week intervals if Hb stabilised in the range of 11-13 g/dL. Upon ascending to >/=13 g/dL, epoetin was discontinued. Iron supplements of 100 mg intravenous doses were given weekly. Of 37 patients who enrolled, 33 could be evaluated. RESULTS AND DISCUSSION: Their median Hb level was 13.7 (10.9-16.2) g/dL at baseline and descended to 11.0 (7.4-13.8) g/dL by the end of chemotherapy. Anaemia (Hb < 10 g/dL) was prevented in 24 patients (73%). The mean dose requirement for epoetin-alpha was 3 x 5,866 U per week per patient, representing a dose reduction of 41%. Treatment failed in nine patients (27%), in part due to epoetin-alpha resistance in four (12%) and blood transfusion in three (9%) patients. CONCLUSION: Dose reduction was as effective as fixed doses in anaemia prophylaxis but reduced the amount of prescribed epoetin substantially. ------>tmu_sno=None ------>sno=19797 ------>authors2=Yeur-Hur Lai ------>authors3= ------>authors4= ------>authors5= ------>authors6= ------>authors6_c= ------>authors=Yu-Hua Chou ------>delete_flag=0 ------>SCI_JNo=None ------>authors2_c=??? ------>publish_area=2 ------>updateTitle=Dose reduction of epoetin-alpha in the prevention of chemotherapy-induced anaemia. ------>language=1 ------>check_flag=None ------>submit_date=None ------>country=None ------>no= ------>patent_SDate=None ------>update_bywho=None ------>publish_year=2008 ------>submit_flag=None ------>publish_month=8 |